Last reviewed · How we verify

Fimasartan; Hydrochlorothiazide

Stendhal Americas, S.A. · Phase 3 active Small molecule

Fimasartan; Hydrochlorothiazide is a Angiotensin II receptor blocker + thiazide diuretic combination Small molecule drug developed by Stendhal Americas, S.A.. It is currently in Phase 3 development for Hypertension. Also known as: Diarakhor, Kanarb plus.

Fimasartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume and sodium reabsorption.

Fimasartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume and sodium reabsorption. Used for Hypertension.

At a glance

Generic nameFimasartan; Hydrochlorothiazide
Also known asDiarakhor, Kanarb plus
SponsorStendhal Americas, S.A.
Drug classAngiotensin II receptor blocker + thiazide diuretic combination
TargetAT1 receptor (fimasartan); sodium-chloride cotransporter (hydrochlorothiazide)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Fimasartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels and other tissues, causing vasodilation and reduced blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urine output and reducing blood volume. The combination provides complementary antihypertensive effects through different mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fimasartan; Hydrochlorothiazide

What is Fimasartan; Hydrochlorothiazide?

Fimasartan; Hydrochlorothiazide is a Angiotensin II receptor blocker + thiazide diuretic combination drug developed by Stendhal Americas, S.A., indicated for Hypertension.

How does Fimasartan; Hydrochlorothiazide work?

Fimasartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume and sodium reabsorption.

What is Fimasartan; Hydrochlorothiazide used for?

Fimasartan; Hydrochlorothiazide is indicated for Hypertension.

Who makes Fimasartan; Hydrochlorothiazide?

Fimasartan; Hydrochlorothiazide is developed by Stendhal Americas, S.A. (see full Stendhal Americas, S.A. pipeline at /company/stendhal-americas-s-a).

Is Fimasartan; Hydrochlorothiazide also known as anything else?

Fimasartan; Hydrochlorothiazide is also known as Diarakhor, Kanarb plus.

What drug class is Fimasartan; Hydrochlorothiazide in?

Fimasartan; Hydrochlorothiazide belongs to the Angiotensin II receptor blocker + thiazide diuretic combination class. See all Angiotensin II receptor blocker + thiazide diuretic combination drugs at /class/angiotensin-ii-receptor-blocker-thiazide-diuretic-combination.

What development phase is Fimasartan; Hydrochlorothiazide in?

Fimasartan; Hydrochlorothiazide is in Phase 3.

What are the side effects of Fimasartan; Hydrochlorothiazide?

Common side effects of Fimasartan; Hydrochlorothiazide include Dizziness, Fatigue, Hyperuricemia, Hypokalemia, Hyperglycemia, Cough.

What does Fimasartan; Hydrochlorothiazide target?

Fimasartan; Hydrochlorothiazide targets AT1 receptor (fimasartan); sodium-chloride cotransporter (hydrochlorothiazide) and is a Angiotensin II receptor blocker + thiazide diuretic combination.

Related